Morningstar backs Australia's Cochlear on new hearing implant product
BUZZ-Morningstar backs Australia's Cochlear on new hearing implant product ** Morningstar reiterates A$110 fair value estimate for Cochlear Ltd COH.AX; says shares are slightly undervalued, is more optimistic than the market on resilience of cochlear implant demand
** Investment research firm says hearing implant maker will benefit from its new product, Nexa
** Says co to realise this from 2H26 as hospital approval bottlenecks resolve and availability improves
** Morningstar notes firm earns large proportion of its revenue from sound processor upgrades and accessories used in implants which offsets risk of increased price pressure from competitors
** Expects 7% average revenue growth from FY27 vs guidance of about 4% in 2H26, driven by Nexa uptake and penetration in emerging markets with faster birthrates and rising affordability
** YTD, COH down 62.9%, as of stock's last close
(Reporting by Aamir Sheik Khalid in Bengaluru)
Recent news on Cochlear
See all newsAustralia's Cochlear set for worst week in more than five months
Australia's Cochlear hit with shareholder lawsuit over 2026 earnings forecast (updated)
Australia's Cochlear falls after shareholder class action over FY2026 profit forecast
Cochlear to defend shareholder class action over 2026 profit forecast
Brief: Cochlear says class action claim filed against it in Supreme Court of Victoria